Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis: A prospective, multi-institutional study

Adam S. Deconde, Jess C. Mace, Jeremiah A. Alt, Rodney J. Schlosser, Timothy Smith, Zachary M. Soler

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Evidence comparing the impact of medical and surgical management of chronic rhinosinusitis on olfactory function is limited. This study evaluates olfactory outcomes in patients who failed initial medical management and elect either continued medical management or endoscopic sinus surgery (ESS) followed by medical management. Methods: Adult subjects were prospectively enrolled into a nonrandomized, multi-institutional cohort. Baseline characteristics, quality-of-life and objective clinical findings were collected along with 2 quality-of-life disease-specific measures, the Rhinosinusitis Disability Index (RSDI) and Sinonasal Outcome Test (SNOT-22). The primary outcome measure was the posttreatment change (≥6 months) in the Brief Smell Identification Test (B-SIT). Bivariate and multivariate analyses compared B-SIT changes by treatment type while controlling for baseline cofactors. Results: Subjects (n = 280) were enrolled between March 2011 and May 2013. Baseline B-SIT scores (mean ± standard deviation) were comparable between medical and surgical treatment groups (8.8 ± 3.2 vs 9.0 ± 3.2; p = 0.703). Subjects with baseline impaired olfaction (n = 83; 29.6%) experienced B-SIT improvement in both the medical (n = 17; 2.3 ± 2.8; p = 0.005) and surgical (n = 66; 2.1 ± 3.0; p <0.001) cohort. A total of 38.6% of subjects with impaired olfaction return to normal olfaction at follow-up with no difference identified between treatment modalities (p = 0.803). Multivariate analyses identified prior surgery as a predictor of less improvement regardless of treatment modality in patients with baseline impaired olfaction. Average changes in B-SIT scores were comparable between treatment groups (p > 0.050). Conclusion: Subjects electing ESS experienced gains in olfaction comparable to subjects electing continued medical management. Further study with larger sample size and more sensitive measures of olfaction are needed to determine differences between treatment groups.

Original languageEnglish (US)
Pages (from-to)725-733
Number of pages9
JournalInternational Forum of Allergy and Rhinology
Volume4
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Smell
Therapeutics
Quality of Life
Sample Size
Multivariate Analysis
Outcome Assessment (Health Care)

Keywords

  • Inflammation
  • Olfaction disorders
  • Quality-of-life
  • Sinusitis
  • Smell
  • Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology
  • Medicine(all)

Cite this

Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis : A prospective, multi-institutional study. / Deconde, Adam S.; Mace, Jess C.; Alt, Jeremiah A.; Schlosser, Rodney J.; Smith, Timothy; Soler, Zachary M.

In: International Forum of Allergy and Rhinology, Vol. 4, No. 9, 2014, p. 725-733.

Research output: Contribution to journalArticle

Deconde, Adam S. ; Mace, Jess C. ; Alt, Jeremiah A. ; Schlosser, Rodney J. ; Smith, Timothy ; Soler, Zachary M. / Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis : A prospective, multi-institutional study. In: International Forum of Allergy and Rhinology. 2014 ; Vol. 4, No. 9. pp. 725-733.
@article{764f6c7f8f6944608782e04dafacb9b8,
title = "Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis: A prospective, multi-institutional study",
abstract = "Background: Evidence comparing the impact of medical and surgical management of chronic rhinosinusitis on olfactory function is limited. This study evaluates olfactory outcomes in patients who failed initial medical management and elect either continued medical management or endoscopic sinus surgery (ESS) followed by medical management. Methods: Adult subjects were prospectively enrolled into a nonrandomized, multi-institutional cohort. Baseline characteristics, quality-of-life and objective clinical findings were collected along with 2 quality-of-life disease-specific measures, the Rhinosinusitis Disability Index (RSDI) and Sinonasal Outcome Test (SNOT-22). The primary outcome measure was the posttreatment change (≥6 months) in the Brief Smell Identification Test (B-SIT). Bivariate and multivariate analyses compared B-SIT changes by treatment type while controlling for baseline cofactors. Results: Subjects (n = 280) were enrolled between March 2011 and May 2013. Baseline B-SIT scores (mean ± standard deviation) were comparable between medical and surgical treatment groups (8.8 ± 3.2 vs 9.0 ± 3.2; p = 0.703). Subjects with baseline impaired olfaction (n = 83; 29.6{\%}) experienced B-SIT improvement in both the medical (n = 17; 2.3 ± 2.8; p = 0.005) and surgical (n = 66; 2.1 ± 3.0; p <0.001) cohort. A total of 38.6{\%} of subjects with impaired olfaction return to normal olfaction at follow-up with no difference identified between treatment modalities (p = 0.803). Multivariate analyses identified prior surgery as a predictor of less improvement regardless of treatment modality in patients with baseline impaired olfaction. Average changes in B-SIT scores were comparable between treatment groups (p > 0.050). Conclusion: Subjects electing ESS experienced gains in olfaction comparable to subjects electing continued medical management. Further study with larger sample size and more sensitive measures of olfaction are needed to determine differences between treatment groups.",
keywords = "Inflammation, Olfaction disorders, Quality-of-life, Sinusitis, Smell, Therapeutics",
author = "Deconde, {Adam S.} and Mace, {Jess C.} and Alt, {Jeremiah A.} and Schlosser, {Rodney J.} and Timothy Smith and Soler, {Zachary M.}",
year = "2014",
doi = "10.1002/alr.21350",
language = "English (US)",
volume = "4",
pages = "725--733",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis

T2 - A prospective, multi-institutional study

AU - Deconde, Adam S.

AU - Mace, Jess C.

AU - Alt, Jeremiah A.

AU - Schlosser, Rodney J.

AU - Smith, Timothy

AU - Soler, Zachary M.

PY - 2014

Y1 - 2014

N2 - Background: Evidence comparing the impact of medical and surgical management of chronic rhinosinusitis on olfactory function is limited. This study evaluates olfactory outcomes in patients who failed initial medical management and elect either continued medical management or endoscopic sinus surgery (ESS) followed by medical management. Methods: Adult subjects were prospectively enrolled into a nonrandomized, multi-institutional cohort. Baseline characteristics, quality-of-life and objective clinical findings were collected along with 2 quality-of-life disease-specific measures, the Rhinosinusitis Disability Index (RSDI) and Sinonasal Outcome Test (SNOT-22). The primary outcome measure was the posttreatment change (≥6 months) in the Brief Smell Identification Test (B-SIT). Bivariate and multivariate analyses compared B-SIT changes by treatment type while controlling for baseline cofactors. Results: Subjects (n = 280) were enrolled between March 2011 and May 2013. Baseline B-SIT scores (mean ± standard deviation) were comparable between medical and surgical treatment groups (8.8 ± 3.2 vs 9.0 ± 3.2; p = 0.703). Subjects with baseline impaired olfaction (n = 83; 29.6%) experienced B-SIT improvement in both the medical (n = 17; 2.3 ± 2.8; p = 0.005) and surgical (n = 66; 2.1 ± 3.0; p <0.001) cohort. A total of 38.6% of subjects with impaired olfaction return to normal olfaction at follow-up with no difference identified between treatment modalities (p = 0.803). Multivariate analyses identified prior surgery as a predictor of less improvement regardless of treatment modality in patients with baseline impaired olfaction. Average changes in B-SIT scores were comparable between treatment groups (p > 0.050). Conclusion: Subjects electing ESS experienced gains in olfaction comparable to subjects electing continued medical management. Further study with larger sample size and more sensitive measures of olfaction are needed to determine differences between treatment groups.

AB - Background: Evidence comparing the impact of medical and surgical management of chronic rhinosinusitis on olfactory function is limited. This study evaluates olfactory outcomes in patients who failed initial medical management and elect either continued medical management or endoscopic sinus surgery (ESS) followed by medical management. Methods: Adult subjects were prospectively enrolled into a nonrandomized, multi-institutional cohort. Baseline characteristics, quality-of-life and objective clinical findings were collected along with 2 quality-of-life disease-specific measures, the Rhinosinusitis Disability Index (RSDI) and Sinonasal Outcome Test (SNOT-22). The primary outcome measure was the posttreatment change (≥6 months) in the Brief Smell Identification Test (B-SIT). Bivariate and multivariate analyses compared B-SIT changes by treatment type while controlling for baseline cofactors. Results: Subjects (n = 280) were enrolled between March 2011 and May 2013. Baseline B-SIT scores (mean ± standard deviation) were comparable between medical and surgical treatment groups (8.8 ± 3.2 vs 9.0 ± 3.2; p = 0.703). Subjects with baseline impaired olfaction (n = 83; 29.6%) experienced B-SIT improvement in both the medical (n = 17; 2.3 ± 2.8; p = 0.005) and surgical (n = 66; 2.1 ± 3.0; p <0.001) cohort. A total of 38.6% of subjects with impaired olfaction return to normal olfaction at follow-up with no difference identified between treatment modalities (p = 0.803). Multivariate analyses identified prior surgery as a predictor of less improvement regardless of treatment modality in patients with baseline impaired olfaction. Average changes in B-SIT scores were comparable between treatment groups (p > 0.050). Conclusion: Subjects electing ESS experienced gains in olfaction comparable to subjects electing continued medical management. Further study with larger sample size and more sensitive measures of olfaction are needed to determine differences between treatment groups.

KW - Inflammation

KW - Olfaction disorders

KW - Quality-of-life

KW - Sinusitis

KW - Smell

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84908344708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908344708&partnerID=8YFLogxK

U2 - 10.1002/alr.21350

DO - 10.1002/alr.21350

M3 - Article

C2 - 25044658

AN - SCOPUS:84908344708

VL - 4

SP - 725

EP - 733

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 9

ER -